AORT ARTIVION, INC.

Q3 2025 10-Q

Filed: Nov 7, 2025Period ending Sep 30, 2025

Health Care

Surgical & Medical Instruments & ApparatusSEC EDGAR

ARTIVION, INC. (AORT) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 7, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Capital expenditures $11.5M for nine months ended Sep 30, 2025 vs $9.8M YoY
• Capex focused on manufacturing equipment, software, computer equipment, and leasehold improvements

+2 more insights

Risk Factors

• New risk: Italian medical device payback reduced by 75% after judicial challenges, finalized 2025 payment ~€0.1M reflecting regulatory/tax risk update
• Updated regulatory risk: FDA Mtb tissue processing guidance withdrawn May 2025, public comments filed, potential to reduce available safe implantable tissue supply

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$113M

Net Income

$7M

Gross Margin

65.6%

Operating Margin

11.1%

Net Margin

5.7%

ROE

1.5%

Total Assets

$858M

Source: XBRL data from ARTIVION, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on ARTIVION, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.